Genealogical tree study in patients with familial paraganglioma syndrome due to SDHD mutation
Med Clin (Barc). 2023 Dec 1:S0025-7753(23)00670-X. doi: 10.1016/j.medcli.2023.10.020. Online ahead of print.NO ABSTRACTPMID:38042737 | DOI:10.1016/j.medcli.2023.10.020 (Source: Medicina Clinica)
Source: Medicina Clinica - December 2, 2023 Category: General Medicine Authors: Ángel López Montalbán V íctor José Simón Frapolli Mar ía José Picón César Source Type: research
An incidental intrapericardial paraganglioma followed up for 11 years
We describe a pericardial paraganglioma with very unusual features: absence of catecholamine hypersecretion or compressive symptoms, located in the right atrium and apparently sporadic. After a curative intended surgery preceded by arterial embolization and preparation with alpha-blockade, there was complete remission with no evidence of local or extracardiac disease within a very long-term follow-up. We provide more evidence on the characterization, management and long-term outcomes of localized non-secretory pericardial paragangliomas. After surgical treatment, we propose lifelong clinical, biochemical, and imaging surve...
Source: Annales d'Endocrinologie - December 1, 2023 Category: Endocrinology Authors: Francisca de Brito Marques Francisco Sim ões de Carvalho Ana Paula Marques Source Type: research
An incidental intrapericardial paraganglioma followed up for 11 years
We describe a pericardial paraganglioma with very unusual features: absence of catecholamine hypersecretion or compressive symptoms, located in the right atrium and apparently sporadic. After a curative intended surgery preceded by arterial embolization and preparation with alpha-blockade, there was complete remission with no evidence of local or extracardiac disease within a very long-term follow-up. We provide more evidence on the characterization, management and long-term outcomes of localized non-secretory pericardial paragangliomas. After surgical treatment, we propose lifelong clinical, biochemical, and imaging surve...
Source: Annales d'Endocrinologie - December 1, 2023 Category: Endocrinology Authors: Francisca de Brito Marques Francisco Sim ões de Carvalho Ana Paula Marques Source Type: research
A rare cause of AA amyloidosis: Glomus tumor and treatment with anakinra —Case report and literature review
AbstractSystemic AA amyloidosis is associated with poorly controlled chronic inflammatory disorders. Chronic infections and inflammatory arthritis are the most common causes; however, they can also rarely occur as a complication of neoplastic disorders. The development of AA amyloidosis secondary to paraganglioma, which is a rare type of tumor, has rarely been reported in the literature. In this case, an 85-year-old female patient with a glomus tumor in the neck, who has been followed up over 50 years, applied with complaints of loss of appetite, nausea, and diarrhea for 5–6 months. While evaluating the patient, who...
Source: International Journal of Rheumatic Diseases - November 28, 2023 Category: Rheumatology Authors: Fatih Tastekin,
Duygu Kerim,
Sait Sen,
Yasemin Kabasakal Tags: CASE REPORT Source Type: research
APOBEC3C is a novel target for the immune treatment of lower-grade gliomas
CONCLUSIONS: A3C is an immune-related prognostic biomarker in LGGs. Developing drugs to block A3C could enhance the efficiency of immunotherapy and improve disease survival.Abbreviation: A3C: Apolipoprotein B mRNA editing catalytic polypeptide-like (APOBEC) type 3C; LGGs: lower-grade gliomas; CGGA: Chinese Glioma Genome Atlas; WGCNA: Weighted gene co-expression network analysis; scRNA: Single-cell RNA; HGG: higher-grade glioma; OS: overall survival; TME: tumor microenvironment; KM: Kaplan-Meier; PFI: progression-free interval; IDH: isocitrate dehydrogenase; ROC: receiver operating characteristic; GS: gene significance; MM:...
Source: Neurological Research - November 26, 2023 Category: Neurology Authors: Shufa Zhao Yuntao Li Jie Xu Liang Shen Source Type: research
APOBEC3C is a novel target for the immune treatment of lower-grade gliomas
CONCLUSIONS: A3C is an immune-related prognostic biomarker in LGGs. Developing drugs to block A3C could enhance the efficiency of immunotherapy and improve disease survival.Abbreviation: A3C: Apolipoprotein B mRNA editing catalytic polypeptide-like (APOBEC) type 3C; LGGs: lower-grade gliomas; CGGA: Chinese Glioma Genome Atlas; WGCNA: Weighted gene co-expression network analysis; scRNA: Single-cell RNA; HGG: higher-grade glioma; OS: overall survival; TME: tumor microenvironment; KM: Kaplan-Meier; PFI: progression-free interval; IDH: isocitrate dehydrogenase; ROC: receiver operating characteristic; GS: gene significance; MM:...
Source: Cell Research - November 26, 2023 Category: Cytology Authors: Shufa Zhao Yuntao Li Jie Xu Liang Shen Source Type: research
